David Beckham's health drink venture, IM8, has announced a significant capital injection of approximately £790 million ($1 billion) from General Catalyst's Customer Value Fund (CVF). This substantial funding, revealed on Tuesday, marks a notable moment for the startup co-founded by the former England football captain, as it seeks to expand its reach in the burgeoning longevity and wellness market.
What makes this funding particularly interesting is the unconventional nature of General Catalyst's CVF. Unlike traditional venture capital firms that take equity stakes in companies, the CVF provides what are essentially loans with unique repayment terms. Startups receiving funding from CVF agree to repay the initial amount along with a fixed, capped percentage of their generated revenue. This structure means that General Catalyst will not acquire any ownership stake in IM8, and crucially for the startup, its existing ownership will not be diluted.
This innovative financing model is designed for companies that possess predictable revenue streams and a clear strategy for leveraging additional capital to accelerate growth. For IM8, which sells a subscription-based vitamin drink containing compounds linked to longevity, this non-dilutive approach is particularly advantageous. The capital is specifically earmarked to finance up to 70% of IM8's customer acquisition costs. In return, General Catalyst will receive a capped share of what it terms 'reference income', defined as revenue generated from these new customers multiplied by a fixed gross-margin assumption. Once General Catalyst recovers its investment and reaches its revenue share cap, all subsequent revenue from those customers will revert entirely to Prenetics, IM8's parent company.
IM8 was co-founded by CEO Danny Yeung, a self-described high-school dropout who previously founded Prenetics, a health company that successfully went public in 2022. It was through these business connections that Yeung met David Beckham, leading to the creation of IM8. The company's core product is a vitamin drink featuring ingredients such as açai fruit extract and Coenzyme Q10, marketed for their potential longevity benefits, sold primarily through a subscription model to consumers.
The move by General Catalyst's CVF to back IM8 with such a substantial sum underscores a growing trend in the investment landscape, offering an alternative path for high-growth companies that wish to avoid equity dilution. This strategy has been previously employed by the fund, notably providing £790 million to Grammerly in May 2025. For UK households and businesses, the rise of such financing models could mean more diverse and innovative products reaching the market, as companies like IM8 are empowered to scale without traditional shareholder pressures. While IM8's direct impact on the broader UK economy remains to be seen, the success of such ventures can contribute to job creation and innovation within the health and wellness sector.